9.1 Inhalation Anesthetics & Nitrous Oxide

9.1 Inhalation Anesthetics & Nitrous Oxide

Inhalational general anesthesia forms the cornerstone of modern surgical care. Volatile halogenated vapors and the inorganic gas nitrous oxide provide dose-dependent hypnosis, amnesia, immobility, and suppression of autonomic reflexes. For the Certified Anesthesia Technologist (Cer.A.T.T.), mastering the physiological, thermodynamic, and chemical properties of these agents is essential for managing anesthesia delivery systems, monitoring vapor delivery, anticipating hemodynamic transitions, and preventing life-threatening equipment-related toxicities.

---

Minimum Alveolar Concentration (MAC)

The potency of inhalational anesthetics is universally quantified using the Minimum Alveolar Concentration (MAC).

Definition and Standardization

MAC is defined as the steady-state alveolar concentration of an inhaled anesthetic gas or vapor at 1 atmosphere of pressure (760 mmHg) that prevents purposeful skeletal muscle movement in 50% of patients exposed to a standard supramaximal noxious stimulus—specifically, a surgical skin incision.

Because end-tidal alveolar gas partial pressure (PA) rapidly equilibrates with pulmonary capillary blood partial pressure (Pa) and ultimately brain tissue partial pressure (Pbr), measuring end-tidal anesthetic gas concentration provides an accurate, non-invasive surrogate for the concentration of anesthetic active at central nervous system target sites. MAC represents an index of immobility, which is mediated primarily at the level of the spinal cord ventral horn motor neurons, rather than higher cortical centers.

Standard MAC Values in Healthy Adults (Ages 30–40 Years)

Anesthetic potency varies inversely with MAC: the lower the numerical MAC value, the more potent the agent. Values are measured when breathing 100% oxygen under normobaric sea-level conditions:

Because nitrous oxide has a MAC of 104%, it cannot achieve surgical immobility (1.0 MAC) as a sole agent under normobaric conditions without causing lethal arterial hypoxemia. However, inhaled anesthetics exhibit additive MAC properties: delivering 0.5 MAC of nitrous oxide (52%) alongside 0.5 MAC of sevoflurane (1.0%) yields an effective total anesthetic depth of 1.0 MAC.

Clinical Derivatives of MAC

• MAC-awake (0.3 to 0.5 MAC): The alveolar concentration at which 50% of patients will open their eyes or respond to verbal commands during emergence from general anesthesia. Voluntary cognitive processing and memory formation recover around this threshold.
• MAC-BAR (1.5 to 2.0 MAC): The alveolar concentration required to Block Autonomic Reflexes (tachycardia, hypertension, diaphoresis, pupillary dilation) in response to surgical incision. When opioids or regional nerve blocks are co-administered, the required MAC-BAR is substantially lowered.
• 1.3 MAC (ED₉₅): Statistically, 1.3 times the MAC value prevents movement in 95% of patients during surgical incision. This represents the standard targeted clinical depth for volatile maintenance in the absence of significant intravenous adjuncts.
• MAC-intubation (1.3 to 1.5 MAC): The concentration required to suppress gross movement and laryngeal reflexes during endotracheal intubation in the absence of neuromuscular blocking drugs.

Factors Influencing MAC

MAC is not a static physiological constant; it is modified by physiological variables, co-administered drugs, and patient age:

FACTORS INCREASING MAC (Higher Vapor Requirement):
- Hyperthermia (elevates metabolic demand and neuronal kinetic energy)
- Chronic alcohol abuse (induces central tolerance and upregulates GABA/NMDA receptors)
- Acute stimulant intoxication (cocaine, amphetamines, ephedrine, MAO inhibitors)
- Hypernatremia (elevates extracellular fluid osmolality)
- Natural red hair phenotype (melanocortin-1 receptor [MC1R] mutation, ~19% MAC increase)
- Infant age peak (highest at 6 months of age)

FACTORS DECREASING MAC (Lower Vapor Requirement):
- Hypothermia (decreases MAC by ~5% to 7% per 1°C drop in core body temperature)
- Advancing age (decreases by ~6% per decade after 40 years)
- Acute alcohol intoxication (additive central GABA-ergic depression)
- Co-administered intravenous anesthetics (opioids, propofol, benzodiazepines, ketamine)
- Alpha-2 adrenergic agonists (dexmedetomidine, clonidine)
- Severe arterial hypoxemia (PaO2 < 38 mmHg) and severe hypotension (MAP < 40 mmHg)
- Severe anemia (hemoglobin < 5 g/dL)
- Pregnancy and immediate postpartum state (progesterone elevation decreases MAC up to 30%)
- Hyponatremia
- Intravenous lidocaine and lithium

FACTORS WITH NO EFFECT ON MAC:
- Duration of anesthesia
- Patient sex / gender
- Arterial hyperoxemia
- Thyroid dysfunction per se (hyper/hypothyroidism alters cardiac output and uptake kinetics, but does not alter intrinsic central neuronal MAC)
- Normocarbia vs. moderate hypercarbia (PaCO2 15 to 90 mmHg)

---

Pharmacokinetics: Solubility, Uptake & Distribution

The rate at which the brain partial pressure (Pbr) reaches an anesthetic concentration is determined by the speed of alveolar wash-in (FA/FI), where FI is the inspired concentration and FA is the alveolar concentration.

Partition Coefficients & Solubility

A partition coefficient describes the ratio of the distribution of an anesthetic between two phases at equilibrium (equal partial pressures). The blood:gas partition coefficient reflects how readily an anesthetic dissolves in blood versus alveolar gas:

• Low Blood:Gas Solubility (Desflurane 0.42, Sevoflurane 0.65): Because very little agent dissolves into the pulmonary capillary blood, the blood acts as a small reservoir. The blood quickly saturates, allowing alveolar partial pressure (FA) to rapidly rise and match inspired concentration (FI). Consequently, arterial partial pressure (Pa) and brain partial pressure (Pbr) rise almost instantaneously, producing rapid induction and ultra-fast emergence.
• High Blood:Gas Solubility (Isoflurane 1.40, Halothane 2.40): The blood acts as a vast "sponge" or sink, absorbing large volumes of vapor molecules before blood partial pressure can rise. Alveolar wash-in (FA/FI) is sluggish, delaying equilibration with the central nervous system, leading to slower induction and prolonged emergence.

Meyer-Overton Hypothesis and Oil:Gas Solubility

The oil:gas partition coefficient measures the solubility of an anesthetic vapor in olive oil, serving as a direct model for neuronal lipid bilayers. The Meyer-Overton hypothesis states that the anesthetic potency of a gas is directly proportional to its lipid solubility. A higher oil:gas coefficient indicates greater lipid solubility, which translates to higher potency and a correspondingly lower MAC value:

$\text{Potency} \propto \text{Oil:Gas Partition Coefficient} \propto \frac{1}{\text{MAC}}$

Halothane has an oil:gas coefficient of 224 and a low MAC of 0.75% (very potent). Desflurane has an oil:gas coefficient of 18.7 and a high MAC of 6.0% (least potent volatile agent).

Concentration Effect and Second Gas Effect

Two unique pharmacokinetic phenomena accelerate the rate of alveolar wash-in when administering high-volume inhalational agents:

1. Concentration Effect: As the delivered inspired concentration (FI) of an anesthetic gas is increased, the rate of rise of alveolar concentration (FA/FI) accelerates disproportionately. This occurs due to two simultaneous physical mechanisms: concentrating effect (the rapid uptake of a large volume of the gas into blood contracts the remaining alveolar gas volume, concentrating the residual molecules) and augmented tracheal inflow (the shrinkage in alveolar volume generates negative pressure, pulling in an additional bolus of fresh gas from the circuit).
2. Second Gas Effect: When a large volume of a rapidly absorbed, low-solubility gas (such as 70% nitrous oxide) is co-administered with a smaller volume of a potent volatile anesthetic (the "second gas", such as 2% sevoflurane), the rapid absorption of nitrous oxide into pulmonary capillaries shrinks total alveolar volume. This concentrates the second gas within the alveolus and pulls in more fresh gas during inspiration, markedly accelerating the rate of rise of FA/FI and speeding induction.

---

Organ System Effects of Inhalation Anesthetics

Volatile anesthetics produce profound, dose-dependent alterations across every major organ system:

Cardiovascular Effects

• Myocardial Contractility: Inhaled halogenated vapors depress myocardial contractility in a dose-dependent manner by inhibiting sarcolemmal L-type calcium channel influx and reducing calcium release from the sarcoplasmic reticulum. Depressant potency ranks: Halothane ≫ Isoflurane = Sevoflurane = Desflurane.
• Systemic Vascular Resistance (SVR): Isoflurane and desflurane induce profound peripheral arteriolar vasodilation, resulting in marked reductions in SVR and Mean Arterial Pressure (MAP). Sevoflurane causes modest reductions in SVR at clinical doses (<1.5 MAC).
• Heart Rate and Autonomic Outflow: Isoflurane and desflurane preserve baroreceptor reflexes and can cause tachycardia. Desflurane, when abruptly increased in concentration (e.g., jumping from 3% to 8%), triggers an acute sympathetic and catecholamine surge via airway and carotid receptor stimulation, causing transient hypertension and tachycardia. Sevoflurane does not increase heart rate at concentrations below 1.5 MAC.
• Cardiac Dysrhythmias: Halothane sensitizes the myocardium to circulating catecholamines, predisposing to ventricular arrhythmias. Modern ethers (isoflurane, sevoflurane, desflurane) do not sensitize the myocardium to epinephrine.
• Coronary Circulation: Isoflurane can dilate small coronary resistance arterioles (<100 μm), historically raising concern for "coronary steal" in patients with critical coronary artery stenosis; however, this is rarely clinically significant under normotensive conditions.

Respiratory Effects

• Ventilatory Depression: Volatile agents cause dose-dependent respiratory depression characterized by decreased tidal volume (VT) with a compensatory, partial increase in respiratory rate (RR). Overall minute ventilation (VE) decreases, resulting in progressive hypercapnia (PaCO₂ rises).
• Blunted CO₂ and Hypoxic Drive: Inhaled agents cause a rightward shift and flattening of the ventilatory response curve to carbon dioxide. Even sub-anesthetic concentrations (0.1 to 0.2 MAC) blunt the peripheral carotid body chemoreceptor response to arterial hypoxemia by 50% to 100%, leaving post-anesthesia patients vulnerable to unrecognized hypoxia.
• Bronchodilation: Halogenated vapors are potent bronchodilators that relax bronchial smooth muscle via direct depletion of intracellular calcium and inhibition of vagal reflex pathways. Sevoflurane is non-pungent, sweet-smelling, and non-irritating to the tracheobronchial tree, making it the usual agent for inhalational mask induction in children; volatile agents are also used as bronchodilators in refractory bronchospasm.
• Airway Irritation: Desflurane and isoflurane are highly pungent vapors. At delivered concentrations exceeding 1.0 MAC in awake or lightly anesthetized patients, they irritate upper airway sensory nerves, triggering coughing, breath-holding, profuse salivation, and life-threatening laryngospasm. Consequently, desflurane and isoflurane must never be used for mask induction.

Central Nervous System Effects

• Cerebral Metabolic Rate (CMRO₂) vs. Cerebral Blood Flow (CBF): Inhaled anesthetics produce dose-dependent suppression of cerebral metabolic rate of oxygen consumption (CMRO₂). However, at concentrations exceeding 0.6 to 1.0 MAC, volatile agents act as direct cerebral vasodilators, causing an increase in cerebral blood flow (CBF). This phenomenon is termed neurovascular uncoupling.
• Intracranial Pressure (ICP): The increase in CBF can elevate intracranial pressure (ICP) in patients with space-occupying intracranial lesions or cerebral edema. Anesthesia providers blunt this response by establishing mild hyperventilation to a PaCO₂ of 30 to 35 mmHg (which constricts cerebral arterioles) prior to introducing volatile agents, or by limiting volatile delivery to <0.5–1.0 MAC while supplementing with intravenous agents.

---

Nitrous Oxide: Physical Properties, Diffusion Hypoxia & Closed Gas Spaces

Nitrous oxide (N₂O) is a colorless, sweet-smelling, non-volatile inorganic gas stored in blue cylinders as a liquid-vapor mixture at an ambient vapor pressure of 745 psig at 20°C.

+-------------------------------------------------------------------------+
|                   NITROUS OXIDE: PHYSICAL PROFILE                       |
| - Molecular Weight: 44.01 g/mol                                         |
| - Blood:Gas Partition Coefficient: 0.47                                 |
| - Oil:Gas Partition Coefficient: 1.4 (Low Potency, MAC = 104%)          |
| - Non-flammable, but supports combustion identically to oxygen          |
| - Mechanism: Non-competitive NMDA receptor antagonist & opioid agonist  |
+-------------------------------------------------------------------------+

Diffusion Hypoxia (The Fink Effect)

Upon discontinuation of nitrous oxide at the end of an anesthetic case, nitrous oxide rapidly leaves pulmonary capillary blood and pours into the alveoli along a steep partial pressure gradient. Because of its low solubility (blood:gas 0.47), large volumes of N₂O flood the alveolar space within the first 5 to 10 minutes.

This rapid influx of N₂O produces two critical consequences:

1. It dilutes alveolar oxygen, driving alveolar PO₂ down to hypoxic levels.
2. It dilutes alveolar carbon dioxide (PCO₂), which lowers arterial PaCO₂, removing the primary medullary respiratory stimulus and inducing hypoventilation.

Clinical Prevention: Cer.A.T.T.s and anesthesia providers must always discontinue nitrous oxide and administer 100% oxygen for at least 5 to 10 minutes at high fresh gas flows to wash out residual alveolar N₂O and prevent diffusion hypoxia.

Expansion of Closed Air Spaces

Nitrous oxide is 34 times more soluble in blood than nitrogen (N₂). When blood saturated with N₂O traverses tissue boundaries adjacent to an air-filled closed body cavity, N₂O diffuses into the cavity 34 times faster than nitrogen can diffuse out into the bloodstream. This discrepancy leads to rapid gas expansion in compliant spaces or dangerous pressure elevations in non-compliant, rigid spaces.

NITROUS OXIDE DIFFUSION GRADIENT IN CLOSED AIR CAVITIES:

   Pulmonary / Capillary Blood                   Closed Air-Filled Cavity
   [High N2O partial pressure]                   [Contains 79% Nitrogen]
              |                                             |
              |==== N2O Enters Rapidly (Solubility 0.47) ==>|
              |                                             |
              |<=== N2 Leaves Sluggishly (Solubility 0.015)=|
              |                                             |
   RESULT: Massive net influx of gas molecules into closed cavity!
           - Compliant cavity: Rapid volume expansion (doubles/triples)
           - Non-compliant cavity: Massive pressure elevation

Clinical Contraindications to Nitrous Oxide

---

Toxic Degradation: Compound A & Carbon Monoxide

Volatile halogenated anesthetics undergo chemical degradation when exposed to carbon dioxide absorbents within the anesthesia breathing circuit, producing toxic byproducts:

Compound A Generation from Sevoflurane

When sevoflurane passes through carbon dioxide absorbents containing strong alkaline bases—specifically barium hydroxide lime (Baralyme) or sodium hydroxide (soda lime)—it undergoes base-catalyzed dehydrofluorination, generating a vinyl ether degradation product known as Compound A (fluoromethyl-2,2-difluoro-1-[trifluoromethyl]vinyl ether):

• Toxicology: In laboratory animal models, Compound A produces dose-dependent renal proximal tubular injury (nephrotoxicity), manifested by proteinuria, glucosuria, elevated blood urea nitrogen (BUN), and serum creatinine elevations.
• Factors Promoting Compound A Formation:
  1. Low Fresh Gas Flow (FGF): Flows <1 L/min allow re-circulation and accumulation of Compound A in the circuit.
  2. Elevated Absorbent Temperatures: High temperatures inside the canister accelerate the chemical reaction.
  3. Desiccated (Partially Dry) Absorbent: Low moisture content accelerates degradation.
  4. High Concentrations of Sevoflurane: High delivered percentage over extended operative durations.
  5. Strong Base Formulations: Barium hydroxide (Baralyme, now discontinued) and sodium hydroxide (soda lime) generate far more Compound A than modern calcium hydroxide absorbents.
• Clinical Practice Standard: U.S. prescribing information for sevoflurane states that fresh gas flows below 1 L/min are not recommended and that exposure at 1 to less than 2 L/min should not exceed 2 MAC-hours; longer exposures therefore use flows of at least 2 L/min.

Carbon Monoxide (CO) Production from Desflurane and Isoflurane

When halogenated ethers containing a difluoromethyl group (-CHF₂) are passed through severely desiccated (bone-dry) carbon dioxide absorbents containing strong bases (potassium hydroxide [KOH] and sodium hydroxide [NaOH]), an exothermic degradation reaction occurs that releases carbon monoxide (CO):

$\text{Desflurane / Isoflurane} + \text{Dry Alkaline Absorbent (KOH/NaOH)} \longrightarrow \text{Carbon Monoxide (CO)} + \text{Heat}$

• Potency of Production: Desflurane > Enflurane > Isoflurane ≫ Halothane = Sevoflurane. Desflurane produces the highest quantities of carbon monoxide, generating carboxyhemoglobin (COHb) concentrations exceeding 30% to 35% in affected patients.
• Classic Failure Scenario: High fresh gas flow (e.g., 10–15 L/min of dry oxygen or air) is left running through an anesthesia machine over a weekend or holiday break. The continuous dry gas flow completely desiccates the absorbent canister. On Monday morning, an induction using desflurane in the desiccated circuit triggers immediate CO production. The patient develops severe, life-threatening cellular hypoxia.
• Diagnostic Pitfall: Standard two-wavelength pulse oximeters (660 nm and 940 nm) cannot distinguish oxyhemoglobin (O₂Hb) from carboxyhemoglobin (COHb). Carboxyhemoglobin absorbs light at 660 nm identically to oxyhemoglobin, causing the pulse oximeter to register a falsely reassuring, normal saturation (e.g., 98%–100%) despite severe tissue asphyxiation. Accurate diagnosis requires multi-wavelength arterial blood gas co-oximetry.
• Cer.A.T.T. Prevention Protocol:
  1. Ensure all fresh gas flows are turned completely off at the end of every operating day.
  2. Inspect and replace carbon dioxide absorbent canisters whenever desiccation is suspected, or when the ethyl violet pH indicator indicates exhaustion.
  3. Utilize modern, alkali-free carbon dioxide absorbents containing calcium hydroxide (Ca(OH)₂, such as Amsorb Plus), which contain no KOH or NaOH and do not produce carbon monoxide or Compound A, even if completely dried.